Skip to main content

Table 1 Characteristics of sixty breast cancer patients treated with neoadjuvant docetaxel plus epirubicin.

From: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Age   
Characteristcs n = 60 (range) %
Median 50 (29 – 67)  
≤ 45 years 18 30
>45 years 42 70
Menopausal status   
Pre 28 46.6
Post 32 53.4
Chemotherapy cycles (median) 3 (2 – 5)  
Clinical Stage   
IIA 12 20
IIB 19 31.7
IIIA 8 13.3
IIIB 18 30
IIIC 3 5
Histology   
Ductal 49 81.7
Lobular 4 6.7
Medular 4 6.7
Outhers 3 5
Histologic grade   
I 16 26.7
II 32 53.3
III 11 18.4
ER   
Positive 45 75
Negative 15 25
PR   
Positive 32 53.3
Negative 28 46.7
P53 protein   
Positive 17 28.3
Negative 43 71.7
P21 protein   
Positive 20 33.3
Negative 40 66.7
HER-2   
Positive 11 18.3
Negative 49 81.7
  1. N = number of patients; ER = estrogen receptor; PR = progesterone receptor.